These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717 [TBL] [Abstract][Full Text] [Related]
6. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor. Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562 [No Abstract] [Full Text] [Related]
7. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A Elife; 2020 Nov; 9():. PubMed ID: 33226337 [TBL] [Abstract][Full Text] [Related]
12. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold. Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity. Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810 [TBL] [Abstract][Full Text] [Related]
15. Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton's Tyrosine Kinase. Harris CM; Foley SE; Goedken ER; Michalak M; Murdock S; Wilson NS SLAS Discov; 2018 Dec; 23(10):1040-1050. PubMed ID: 29991334 [TBL] [Abstract][Full Text] [Related]
16. High-Throughput Implementation of the NanoBRET Target Engagement Intracellular Kinase Assay to Reveal Differential Compound Engagement by SIK2/3 Isoforms. Jin HY; Tudor Y; Choi K; Shao Z; Sparling BA; McGivern JG; Symons A SLAS Discov; 2020 Feb; 25(2):215-222. PubMed ID: 31849250 [TBL] [Abstract][Full Text] [Related]
17. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
18. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711 [TBL] [Abstract][Full Text] [Related]
19. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis. Pery N; Rizvi NB; Shafiq MI J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204 [TBL] [Abstract][Full Text] [Related]
20. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors. Diao Y; Fang X; Song P; Lai M; Tong L; Hao Y; Dou D; Liu Y; Ding J; Zhao Z; Xie H; Li H Bioorg Med Chem; 2019 Aug; 27(15):3390-3395. PubMed ID: 31221612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]